The PARADIGM-HF and PARAGON-HF trials demonstrated consistent benefits of sacubitril/valsartan relative to RAS inhibitors in ...

[26] The study was conducted ... in this study were on enalapril 5 mg/day, diuretics, and/or digitalis for ≥3 months prior to baseline assessment. Valsartan 80 mg/day was administered to ...

Blood lipid levels were as follows: triglycerides at 3.86 mmol/L, total cholesterol at 5.56 mmol/L, high-density lipoprotein cholesterol at 1.26 ... (500 mg, three times daily) for long-term ...

The following is a summary of “Impact of Race on Sacubitril/Valsartan use of HF,” published in the October 2024 issue of Cardiology by Lu et al. There is limited understanding of how self-reported ...

In this week’s View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart ...

Sacubitril/valsartan significantly reduces NT-proBNP levels in patients with heart failure with reduced ejection fraction (HFrEF) over 3 years, with no significant changes in sST2 and galectin-3.

Matsumoto S, Shen L, Henderson AD, et al. This study is a post hoc analysis of the PARADIGM-HF randomized trial, which demonstrated a benefit of sacubitril/valsartan compared to enalapril in patients ...

Your browser does not support the audio element. MG Motor has released the first set of images and details of an all-new ES5 electric SUV. The ES5 will be a global ...

Sacubitril/valsartan may be a better treatment option compared with ACEi/ARBs for patients with malignant hypertension-associated thrombotic microangiopathy. Kidney recovery is better when thrombotic ...

In July this year the SAIC owned brand launched the new 2024 variant of the MG HS, boasting a new facelift, improved, modernized, interior features and a hybrid version with a 24.7 kWh battery ...